GLI2 as A Potential Drug Target for Gliomas (G2736)

Target Name: GLI2

NCBI ID: G2736

GLI2

GLI2 as A Potential Drug Target for Gliomas

GLI2 (Glioma-Associated Oncogene Family Zinc Finger 2) is a protein that is expressed in various tissues, including the brain, and is known to play a role in the development and progression of gliomas, which are a type of cancer that affects the brain. GLI2 has also been shown to be involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Recent studies have suggested that GLI2 may be a potential drug target or biomarker for the treatment of gliomas. One reason for this is that GLI2 has been shown to be highly expressed in glioma tissues and has been shown to be involved in the development and progression of these diseases. Additionally, GLI2 has been shown to interact with several other proteins that are known to be involved in the development and progression of gliomas, including the oncogene PDGF-BB.

Another potential reason for GLI2's potential as a drug target is its role in the regulation of cell apoptosis. Gliomas are often characterized by the loss of normal brain cells, and the failure of GLI2 to regulate cell apoptosis has been implicated in the development and progression of these diseases. Additionally, GLI2 has been shown to play a role in the regulation of angiogenesis, which is the formation of new blood vessels, and the failure of GLI2 to regulate angiogenesis has been implicated in the development and progression of gliomas.

In addition to its role in the regulation of cell apoptosis and angiogenesis, GLI2 has also been shown to play a role in the regulation of cell growth. Gliomas are often characterized by the loss of normal brain cells, and the failure of GLI2 to regulate cell growth has been implicated in the development and progression of these diseases.

Gliomas are a type of cancer that affects the brain and are characterized by the loss of normal brain cells. These diseases are often difficult to treat and have a poor prognosis. GLI2 has been shown to play a role in the development and progression of gliomas, and as a potential drug target or biomarker, GLI2 may be a useful target for the treatment of these diseases.

In conclusion, GLI2 (Glioma-Associated Oncogene Family Zinc Finger 2) is a protein that is expressed in various tissues and is known to play a role in the development and progression of gliomas. GLI2 has also been shown to interact with several other proteins that are involved in the development and progression of these diseases, and its failure to regulate cell apoptosis, angiogenesis, and cell growth may make it a potential drug target or biomarker for the treatment of gliomas. Further research is needed to fully understand the role of GLI2 in the development and progression of gliomas and its potential as a drug target or biomarker.

Protein Name: GLI Family Zinc Finger 2

Functions: Functions as transcription regulator in the hedgehog (Hh) pathway (PubMed:18455992, PubMed:26565916). Functions as transcriptional activator (PubMed:9557682, PubMed:19878745, PubMed:24311597). May also function as transcriptional repressor (By similarity). Requires STK36 for full transcriptional activator activity. Required for normal embryonic development (PubMed:15994174, PubMed:20685856)

The "GLI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets